A sign for the European Central Bank (ECB) outside the bank’s headquarters in Frankfurt, Germany, on Thursday, Feb. 2, 2023. Alex Kraus | Bloomberg | Getty Images European Central Bank policymakers are reconsidering the path of interest rate hikes in light of last month’s banking turmoil, but remain committed to reining in core inflation. Contagion
0 Comments
In this article JPM MOMO LCID BLK Follow your favorite stocksCREATE FREE ACCOUNT Getty Images Check out the companies making headlines in premarket trading. JPMorgan Chase – The banking behemoth popped more than 5% after posting record revenue that surpassed analyst expectations due to higher interest rates. JPMorgan Chase reported revenue of $39.34 billion, beating
0 Comments
In this article DPZ CZR TXRH COST CRWD Follow your favorite stocksCREATE FREE ACCOUNT Domino’s will roll out 800 custom-branded 2023 Chevy Bolt electric vehicles at locations across the U.S. in the coming months. Domino’s Wall Street analysts are focusing on companies that are well-positioned to navigate the ongoing economic turmoil and emerge stronger. Here
0 Comments
We’re awash in knowledge in 2023, but do you think our general level of understanding is greater? Do you think we’re wiser? I’m not so sure, so when I was challenged to re-read through one of the great collections of ancient wisdom last month, the book of Proverbs, it was an easy Yes. Indeed, I
0 Comments
Tax Day is just around the corner. The Tax Deadline to file your 2022 taxes is April 18, 2023. If you cannot complete your taxes by the tax filing deadline, you can request an automatic six-month extension to file your taxes. If you were wondering, the deadline to apply for a tax extension also falls
0 Comments
Adene Sanchez | E+ | Getty Images Company: Exelixis (EXEL) Business: Exelixis, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. They have produced four marketed pharmaceutical products, including their flagship molecule, cabozantinib. Stock Market Value: $6.3B ($19.46 per share) Activist: Farallon Capital
0 Comments